Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition

No abstract is available for this paper.

• Publication year

  2013

• Venue

  International Journal of Cancer

• Publication date

  2013-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.27781PMID 22948716PMCID PMC4706358
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.

  2011cited by this paper
• GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

  2011cited by this paper
• Recent advances in neuroblastoma.

  2010cited by this paper
• Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models

  2010cited by this paper
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

  2010cited by this paper
• Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability

  2010cited by this paper
• Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target.

  2010cited by this paper
• NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.

  2010cited by this paper
• Antitumor activity of an allosteric inhibitor of centromere-associated protein-E

  2010cited by this paper
• Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.

  2010cited by this paper
• Trk Receptor Expression and Inhibition in Neuroblastomas

  2009cited by this paper
• Inhibition of ALK Signaling for Cancer Therapy

  2009cited by this paper
• The activity of extracellular signal-regulated kinase is required during G2/M phase before metaphase–anaphase transition in synchronized leukemia cell lines

  2009cited by this paper
• Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.

  2009cited by this paper
• Oncogenic mutations of ALK kinase in neuroblastoma

  2008cited by this paper
• Centromere-Associated Protein E: A Motor That Puts the Brakes on the Mitotic Checkpoint

  2008cited by this paper
• Knockdown of B-Raf impairs spindle formation and the mitotic checkpoint in human somatic cells

  2008cited by this paper
• Activating mutations in ALK provide a therapeutic target in neuroblastoma

  2008cited by this paper
• Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

  2008cited by this paper
• Targeted anti-mitotic therapies: can we improve on tubulin agents?

  2007cited by this paper
• Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway

  2007cited by this paper
• Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.

  2005cited by this paper
• Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference.

  2005cited by this paper
• Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay.

  2004cited by this paper
• The discovery of receptor tyrosine kinases: targets for cancer therapy

  2004cited by this paper
• The MAP kinase pathway is required for entry into mitosis and cell survival

  2004cited by this paper
• Targeting the mitogen-activated protein kinase cascade to treat cancer

  2004cited by this paper
• Activating and silencing the mitotic checkpoint through CENP-E-dependent activation/inactivation of BubR1.

  2003cited by this paper
• Targeting RAS signalling pathways in cancer therapy

  2003cited by this paper
• Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells

  2000cited by this paper
• MEK Inhibition Enhances Paclitaxel-induced Tumor Apoptosis*

  2000cited by this paper
• Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

  1999cited by this paper
• Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts.

  1999cited by this paper
• Active MAP Kinase in Mitosis: Localization at Kinetochores and Association with the Motor Protein CENP-E

  1998cited by this paper
• CENP-E Function at Kinetochores Is Essential for Chromosome Alignment

  1997cited by this paper

• From Motor Proteins to Oncogenic Factors: The Evolving Role of Kinesin Superfamily Proteins in Breast Cancer Development.

  2025cites this paper
• Targeting Kinesins for Therapeutic Exploitation of Chromosomal Instability in Lung Cancer

  2025cites this paper
• The role of kinesin family members in hepatobiliary carcinomas: from bench to bedside

  2024cites this paper
• Network pharmacology and molecular docking analysis on the mechanism of Wensan tincture in the treatment of pulmonary nodules: A review

  2024cites this paper
• Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma

  2024cites this paper
• Kinesin-7 CENP-E in tumorigenesis: Chromosome instability, spindle assembly checkpoint, and applications

  2024cites this paper
• Combining Single-Cell and Transcriptomic Data Revealed the Prognostic Significance of Glycolysis in Pancreatic Cancer

  2022cites this paper
• Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.

  2020cites this paper
• Current and Future Strategies for Treatment of Relapsed Neuroblastoma

  2019cites this paper
• Mechanisms of kinesin‐7 CENP‐E in kinetochore–microtubule capture and chromosome alignment during cell division

  2019cites this paper
• CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response

  2018cites this paper
• CENP‐E as a target for cancer therapy: Where are we now?

  2018cites this paper
• Quantum computational studies, spectroscopic (FT-IR, FT-Raman and UV–Vis) profiling, natural hybrid orbital and molecular docking analysis on 2,4 Dibromoaniline

  2018cites this paper
• Mechanisms of Chromosome Congression during Mitosis

  2017cites this paper
• Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor

  2017cites this paper
• MEK inhibitor CI-1040 induces apoptosis in acute myeloid leukemia cells in vitro.

  2016cites this paper
• Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents

  2016cites this paper
• Synthetic Studies on Centromere-Associated Protein-E (CENP-E) Inhibitors: 2. Application of Electrostatic Potential Map (EPM) and Structure-Based Modeling to Imidazo[1,2-a]pyridine Derivatives as Anti-Tumor Agents.

  2015cites this paper
• Genomic Alterations and Abnormal Cell Cycle in High-Risk Neuroblastoma

  2015cites this paper
• Formation of multiprotein assemblies in the nucleus: the spindle assembly checkpoint.

  2014cites this paper
• Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway

  2013cites this paper